4-propoxyphenyl glycidyl ether | 56704-18-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 4-propoxyphenyl glycidyl ether
• 英文别名: 2-[(4-propoxyphenoxy)methyl]oxirane
• CAS: 56704-18-8
• 化学式: C₁₂H₁₆O₃
• 分子量: 208.257
• InChiKey: GUZXNTWZQHTMJJ-UHFFFAOYSA-N

物化性质

• 沸点：
  317.6±12.0 °C(Predicted)
• 密度：
  1.091±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  2.5
• 重原子数：
  15
• 可旋转键数：
  6
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  31
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-(2-aminoethylamino)-1,3,5-trimethylpyrimidine-2,6(1H,3H)-dione 、 4-propoxyphenyl glycidyl ether 在 甲醇 作用下， 以It is obtained in a yield of 32% of theory in the form of colorless crystals which的产率得到1-(4-Propoxyphenoxy)-3-[2-(1,3,5-trimethylpyrimidine-2,4-dion-6-ylamino)-ethylamino]-propan-2-ol
  参考文献：
  名称：

  Cardioactive aryloxypropanolamines

  摘要：

  本发明提供了一般式为：##STR1##的芳氧基丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可能相同或不同，是氢或卤素原子或低碳基、氰基、羧酰胺基、羟基、低酰氧基、低烷氧基、低烯氧基或芳基低烷氧基基团，R.sub.5和R.sub.6，可能相同或不同，是氢原子或低碳基基团，X是直链或支链烷基链，含有2至6个碳原子，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个不是氢原子时，也可以是苯基基团，但是当A是尿嘧啶-6-基团时，尿嘧啶基团的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可能相同或不同，是来自氢、卤素、硝基、羟胺基、氨基、低酰胺基、低烷基氨基、二-(低烷基)-氨基、羟乙基氨基、二-(羟乙基)-氨基、羟基、低烷氧基、烯丙氧基、甲氧基低烷氧基、氰基、羧酰胺基、羧基、低烷氧基羧酰基、羟甲基、低烷氧甲基、卤甲基、氨基甲基、低酰氨基甲基、二-(低烷基)-氨基甲基、吡咯烷基甲基、哌啶基甲基、二-(羟乙基)-氨基甲基、吗啉基甲基、哌嗪基甲基、4-低酰基哌嗪基甲基、4-低烷基哌嗪基甲基、低烷基、低烯基、2-氰乙基、2-(低烷氧羰基)-乙基、2-羧乙基、2-羟乙基、苯基低烷基和苯基的单价或二价取代基，其中苯基基团可选地取代1或2个羟基或甲氧基，或来自氧或硫；其光学活性形式和其外消旋混合物，以及其药理兼容的盐。本发明还提供了制备这些化合物的方法和含有它们的制药组合物。

  公开号：

  US04438128A1
• 作为产物：
  描述：

  4-苄氧基苯酚 在 palladium on activated charcoal 氢氧化钾 、 氢气 、 potassium carbonate 、 sodium iodide 作用下， 以 乙醇 、 丙酮 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 48.0h， 生成 4-propoxyphenyl glycidyl ether
  参考文献：
  名称：

  β1- and β2-Adrenoceptor antagonist activity of a series of para-substituted N-isopropylphenoxypropanolamines

  摘要：

  To further explore the structure-activity relationships of beta-adrenoceptor (beta-AR) antagonists, a series of 25 para-substituted N-isopropylphenoxy-propanolamines were synthesised, nine of which are new compounds. All have been examined for their ability to antagonise beta(1)-ARs in rat atria and beta(2)-ARs in rat trachea. Substitution in the para-position of the phenyl ring is thought to confer B-3-specificity and the selectivity of these compounds for the beta(1)-AR ranges from 1.5-234. None of the compounds tested were selective for the beta(2)-AR. Of the 25 compounds studied, 22 had reasonable (pA(2) > 7) potencies for the rat beta(1)-AR. Only compound I displayed reasonable (pA(2) > 7) potency for the rat beta(2)-AR. Twenty two compounds were used as the training set for comparative molecular field analysis (CoMFA) of antagonist potency (pA(2)) at the rat beta(1)- and beta(2)-ARs. The inclusion of a number of additional physical characteristics improved the QSAR analysis over models derived solely using the CoMFA electrostatic and steric fields. The final models predicted the beta(1)- and beta(2)-AR potency of the compounds in the training set with high accuracy (r(2) = 0.93 and 0.86 respectively). The final beta(1)-AR model predicted the beta(1)-potencies of two out of the three test compounds, not included in the training set, with residual pA(2) values < -0.14, whereas the test compounds were not as well predicted by our final beta(2)-AR model (residual pA(2) values < -0.38). (C) 1999 Editions scientifiques et medicales Elsevier SAS.

  DOI：

  10.1016/s0223-5234(99)00114-2

文献信息

• Cardioactive pyrazole and imidazole aryloxypropanolamines
  申请人：Boehringer Mannheim GmbH

  公开号：US04608383A1

  公开（公告）日：1986-08-26

  The present invention provides aryloxypropanolamines of the general formula: ##STR1## wherein R.sub.1, R.sub.2, R.sub.3 and R.sub.4, which may be the same or different, are hydrogen or halogen atoms or lower alkyl, cyano, carboxamide, hydroxyl, lower acyloxy, lower alkoxy, lower alkenyloxy or aryl lower alkoxy radicals, R.sub.5 and R.sub.6, which may be the same or different, are hydrogen atoms or lower alkyl radicals, X is a straight or branched alkylene chain containing 2 to 6 carbon atoms, A is a mono-, bi- or tricyclic heteroaromatic or hydroheteroaromatic radical or, when at least one of the symbols R.sub.1, R.sub.2, R.sub.3 and R.sub.4 is other than a hydrogen atom, may also be a phenyl radical, with the proviso that when A is a uracil-6-yl radical, the 5-position of the uracil moiety does not contain a hydrogen atom, R.sub.7, R.sub.8, R.sub.9, R.sub.10 and R.sub.11, which may be the same or different, are mono- or divalent substituents selected from hydrogen, halogen, notro, hydraxylamino, amino, lower acylamino, lower alkylamino, di-(lower alkyl)-amino, hydroxyethylamino, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acylaminomethyl, halomethyl, aminomethyl, lower acylaminomethyl, di(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-amino, hydroxyl, lower alkoxy, allyloxy, methoxy lower alkoxy, cyano, carboxamido, carboxy, lower alkoxycarbonyl, hydroxymethyl, lower alkoxymethyl, halomethyl, aminomethyl, lower acyaminomethyl, di-(lower alkyl)-aminomethyl, pyrrolidinomethyl, piperidinomethyl, di-(hydroxyethyl)-aminomethyl, morpholinomethyl, piperazinomethyl, 4-lower acylpiperazinomethyl, 4-lower alkylpiperazinomethyl, lower alkyl, lower alkenyl, 2-cyanoethyl, 2-hydroxyethyl, phenyl lower alkyl and phenyl, the phenyl radicals being optionally substituted with 1 or 2 hydroxyl or methoxy radicals, or from oxygen or sulphur; the optically-active forms and the racemic mixtures thereof, and the pharmacologically compatible salts thereof. The present invention also provides processes for the preparation of these compounds and pharmaceutical compositions containing them. These compounds are useful for the prophylaxis and combatting of cardiac and circulatory diseases.

  本发明提供了通式为：##STR1##的芳基氧代丙醇胺，其中R.sub.1、R.sub.2、R.sub.3和R.sub.4，可以相同也可以不同，是氢或卤素原子或较低的烷基、氰基、羧酰胺、羟基、较低的酰氧基、较低的烷氧基、较低的烯基氧基或芳基较低的烷氧基基团，R.sub.5和R.sub.6，可以相同也可以不同，是氢原子或较低的烷基基团，X是含有2至6个碳原子的直链或支链烷基链，A是单环、双环或三环杂芳基或羟杂芳基基团，或者当R.sub.1、R.sub.2、R.sub.3和R.sub.4中至少有一个符号不是氢原子时，也可以是苯基基团，但是当A是尿嘧啶-6-基基团时，尿嘧啶部分的5位不含氢原子，R.sub.7、R.sub.8、R.sub.9、R.sub.10和R.sub.11，可以相同也可以不同，是从氢、卤素、硝基、羟胺基、氨基、较低的酰胺基、较低的烷基氨基、二(较低烷基)氨基、羟乙基氨基、二(羟乙基)氨基、羟基、较低的烷氧基、烯丙氧基、甲氧基较低的烷氧基、氰基、羧酰胺基、羧基、较低的烷氧羰基、羟甲基、较低的烷氧甲基、卤甲基、氨基甲基、较低的酰氨基甲基、卤甲基、氨基甲基、较低的酰氨基甲基、二(较低烷基)-氨基甲基、吡咯烷甲基、哌啶甲基、二(羟乙基)-氨基甲基、吡咯啉甲基、哌嗪甲基、4-较低的酰基哌嗪甲基、4-较低的烷基哌嗪甲基、较低的烷基、较低的烯基、2-氰基乙基、2-羟基乙基、苯基较低的烷基和苯基等单价或二价取代基，其中苯基基团可以选择性地取代1或2个羟基或甲氧基基团，或者从氧或硫；其光学活性形式和外消旋混合物，以及其药理兼容盐。本发明还提供了制备这些化合物的方法和含有它们的药物组合物。这些化合物对于预防和治疗心脏和循环疾病非常有用。
• Design and Synthesis of AMPK Activators and GDF15 Inducers
  作者：Meijian Zhang、Andrea Bagán、Donna Martínez、Emma Barroso、Xavier Palomer、Santiago Vázquez、Carmen Escolano、Manuel Vázquez-Carrera

  DOI：10.3390/molecules28145468

  日期：——

  Targeting growth differentiation factor 15 (GDF15) is a recent strategy for the treatment of obesity and type 2 diabetes mellitus (T2DM). Here, we designed, synthesized, and pharmacologically evaluated in vitro a novel series of AMPK activators to upregulate GDF15 levels. These compounds were structurally based on the (1-dibenzylamino-3-phenoxy)propan-2-ol structure of the orphan ubiquitin E3 ligase subunit protein Fbxo48 inhibitor, BC1618. This molecule showed a better potency than metformin, increasing GDF15 mRNA levels in human Huh-7 hepatic cells. Based on BC1618, structural modifications have been performed to create a collection of diversely substituted new molecules. Of the thirty-five new compounds evaluated, compound 21 showed a higher increase in GDF15 mRNA levels compared with BC1618. Metformin, BC1618, and compound 21 increased phosphorylated AMPK, but only 21 increased GDF15 protein levels. Overall, these findings indicate that 21 has a unique capacity to increase GDF15 protein levels in human hepatic cells compared with metformin and BC1618.

  靶向生长分化因子 15（GDF15）是近年来治疗肥胖症和 2 型糖尿病（T2DM）的一种策略。在此，我们设计、合成了一系列新型 AMPK 激活剂，并对其进行了体外药理评估，以上调 GDF15 的水平。这些化合物在结构上基于孤儿泛素 E3 连接酶亚基蛋白 Fbxo48 抑制剂 BC1618 的（1-二苄基氨基-3-苯氧基）丙-2-醇结构。与二甲双胍相比，该分子具有更好的效力，能提高人 Huh-7 肝细胞中 GDF15 mRNA 的水平。在 BC1618 的基础上，人们对其进行了结构改造，创造出了一系列不同替代的新分子。在评估的 35 种新化合物中，与 BC1618 相比，化合物 21 显示出更高的 GDF15 mRNA 水平增幅。二甲双胍、BC1618 和化合物 21 增加了磷酸化 AMPK，但只有 21 增加了 GDF15 蛋白水平。总之，这些研究结果表明，与二甲双胍和 BC1618 相比，21 具有增加人肝细胞中 GDF15 蛋白水平的独特能力。
• Aryloxypropanolamine, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
  申请人：BOEHRINGER MANNHEIM GMBH

  公开号：EP0042593A1

  公开（公告）日：1981-12-30

  Die neuen Verbindungen der allgemeinen Formel in der R1-C6 jeweils Wasserstoff, Alkyl oder ggf. weitere Substituenten, A einen Heterocyclus, X eine Alkylenkette und R7-R11 ein- oder zweibindige Reste, wie Wasserstoff, Halogen, Nitro usw. bzw. Sauerstoff oder Schwefel, bedeuten, haben cardiotone und/oder ß-rezeptoren-blockierende Wirkungen und können daher zur Behandlung und Prophylaxe von Herz- und Kreislauferkrankungen verwendet werden. Verfahren zu ihrer Herstellung sowie Arneimittel, die diese Verbindungen enthalten, werden beschrieben.

  通式如下的新化合物 其中 R1-C6 各为氢、烷基或可选的进一步取代基，A 为杂环，X 为亚烷基链，R7-R11 为单价或二价基，如氢、卤素、硝基等或氧或硫，具有强心和/或 ß 受体阻断作用，因此可用于治疗和预防心血管疾病。本文介绍了这些化合物的制备方法和含有这些化合物的药物。
• FLUOROPOLYETHER COMPOUND, AND LUBRICANT AND MAGNETIC DISC COMPRISING SAME
  申请人：Moresco Corporation

  公开号：EP3081549A1

  公开（公告）日：2016-10-19

  A compound of the formula (1), lubricant containing the compound and magnetic disk         R1-C6H4O-CH2CH(OH)CH2OCH2-R2-CH2-O-CH2CH(OH)CH2-OC6H4-R1     (1) wherein R1 is alkoxyl having 1 to 4 carbon atoms, amino or amido, R2 is -CF2CF2O(CF2CF2CF2O)zCF2CF2- or -CF2CF2CF2O(CF2CF2CF2CF2O)nCF2CF2CF2-, z is a real number of 1 to 15, n is a real number of 0 to 4.

  式 (1) 的化合物、含有该化合物的润滑剂和磁性盘 r1-c6h4o-ch2ch(oh)ch2och2-r2-ch2-o-ch2ch(oh)ch2-oc6h4-r1 (1) 其中 R1 是具有 1 至 4 个碳原子的烷氧基、氨基或氨基，R2 是-CF2CF2O(CF2CF2CF2O)zCF2CF2-或 -CF2CF2CF2O(CF2CF2CF2CF2O)nCF2CF2CF2-，z 是 1 至 15 的实数，n 是 0 至 4 的实数。
• FLUOROPOLYETHER COMPOUND, LUBRICANT, AND MAGNETIC DISK
  申请人：Moresco Corporation

  公开号：EP3162836A1

  公开（公告）日：2017-05-03

  An object of the present invention is to provide a compound that can inactivate active alumina in a magnetic head, a lubricant having decomposition resistance, and a magnetic disk using the lubricant. The present invention relates to a fluoropolyether compound represented by formula (1):         R1-CH2-R2-CH2-R3 wherein R1 is C1-C10 alkoxy; R2 is-(CF2)pO(CF2O)x(CF2CF2O)y(CF2CF2CF2O)z(CF2CF2CF2CF2O)w(CF2)p-; x and y are each a real number of 0 to 30; z is a real number of 0 to 30; w is a real number of 0 to 20; p is an integer of 1 to 3; R3 is-OCH2CH(OH)CH2OH, -OCH2CH(OH)CH2OCH2CH(OH)CH2OH, -O(CH2)mOH, or-OCH2 (OH) CHCH2-OC6H4-R4; m is an integer of 2 to 8; and R4 is hydrogen, C1-C4 alkoxy, amino, or an amide residue; and also relates to a lubricant comprising the compound and to a magnetic disk.

  本发明的目的是提供一种能使磁头中的活性氧化铝失活的化合物、一种具有抗分解性的润滑剂和一种使用该润滑剂的磁盘。本发明涉及一种由式（1）表示的氟聚醚化合物： R1-CH2-R2-CH2-R3 其中 R1 是 C1-C10 烷氧基；R2 是-(CF2)pO(CF2O)x(CF2CF2O)y(CF2CF2CF2O)z(CF2CF2CF2CF2O)w(CF2)p-；x 和 y 分别是 0 至 30 的实数；z 是 0 至 30 的实数；w 是 0 至 20 的实数；p 是 1 至 3 的整数；R3是-OCH2CH(OH)CH2OH、-OCH2CH(OH)CH2OCH2CH(OH)CH2OH、-O(CH2)mOH或-OCH2(OH)CHCH2-OC6H4-R4；m是2至8的整数；R4是氢、C1-C4烷氧基、氨基或酰胺残基；还涉及包含该化合物的润滑剂和磁盘。